Key Highlights

● Third-quarter Revenue rose 23% to about $411.5 million.

● Net loss shrank to about $15 million from $80 million.

● Adjusted EBITDA was about $25.5 million, up from roughly $1.5 million.

● Full-year revenue guidance was raised to between $1.60 billion and $1.605 billion.

Tempus AI (NASDAQ:TEM) opened the week with a Quarterly Report that showed faster growth, a far smaller net loss and a higher revenue guide for the full year. The precision-medicine company, which combines genomic testing with a large library of clinical data and artificial intelligence tools, reported on Monday morning, before American markets opened, that third-quarter revenue rose 23% from a year earlier to about $411.5 million.

Founder and Chief Executive Officer Eric Lefkofsky called it another record quarter. Adjusted Earnings before interest, taxes, Depreciation and amortization came in at about $25.5 million, up from roughly $1.5 million a year ago, while the net loss shrank to about $15 million from $80 million. Full-year revenue guidance was raised to between one point six zero and $1.605 billion.

Behind those numbers sit several threads that matter to anyone following the company: strong growth in oncology testing, a rapid ramp in tests that look for minimal residual disease, large data-licensing agreements with drugmakers, two new regulatory clearances for cardiology software and an Acquisition that has cleared a regulatory hurdle.

What did Tempus AI report for the quarter?

Total revenue reached roughly $411.5 million, compared with about $334 million a year earlier. Gross earnings, meaning revenue less direct costs, grew by about 27% to roughly $267 million.

The net loss was about $14.9 million, against a loss of $80 million a year earlier. That reported figure included about $51 million of stock-based compensation and related payroll taxes and about $43 million of unrealized gains on marketable securities, so the swing in the Bottom Line reflects both operating progress and non-operating items.

Cash and marketable securities totaled about $854 million at the end of September. The company also reported adjusted Earnings Per Share of $0.07, which According to market data, compared with a consensus figure of $0.01, though adjusted measures exclude several recurring costs and should be read alongside the reported loss.

How did the two Business lines perform?

The company reports two segments. Diagnostics, which covers genomic testing for cancer and other conditions, produced about $303.5 million of revenue, up 20%. Data and applications, which licenses de-identified data and software to pharmaceutical companies and others, produced about $108 million, up 33%.

Within diagnostics, oncology testing Volume grew 32%. The hereditary testing line was far slower, with revenue growing only about 3%, a gap that shows how much of the segment's momentum rests on cancer tests rather than inherited-disease panels. Within the data segment, insights revenue grew 29%.

The mix matters because the two segments behave differently. Testing revenue depends on physician ordering, reimbursement and volume. Data licensing revenue depends on multi-year agreements with drug developers and can be uneven from quarter to quarter, so the company often discusses contract bookings as well as recognized revenue.

What is happening with minimal residual disease testing?

Minimal residual disease tests look for traces of cancer in the blood after treatment, helping doctors judge whether disease is coming back before it shows up on a scan. Tempus said volume reached about 12,000 tests in the quarter, roughly four times the level of a year earlier.

The test is also tied to the company's oncology franchise. Doctors who already order a tumor profile for a patient can follow with monitoring tests later, which creates repeat volume from the same relationship. The release gave the volume and growth figures only and did not break out revenue for the line.

A rise of that size from a small base is not a measure of overall earnings, and the release does not give revenue per test for the line. Still, it shows that physician and patient uptake is rising.

Readers should keep in mind that reimbursement for newer tests from public and private insurers is a decisive Factor in how fast such lines can scale. The company does not provide payer coverage details in the release, and coverage decisions can change the Economics of a test substantially.

What did the company raise its guidance to?

Management lifted its full-year revenue guidance to a range of one point six zero to $1.605 billion, which it described as growth of about 25% over the prior year. According to market data, the midpoint is slightly above the consensus figure of $1.6 billion that data providers had compiled.

Guidance for full-year adjusted EBITDA was maintained at about $65 million. That means the company did not raise its adjusted earnings guide even as it lifted revenue, a pattern coverage noted without explanation. Because adjusted EBITDA reached about $26 million in this quarter alone, the maintained figure implies a slower pace of improvement in the remaining months of the year.

The shares were reported higher in early trading after the report, with Market data citing a gain of about 4% before the open and another gauge showing a larger move.

Which pharmaceutical deals did the company highlight?

The headline agreement is a licensing arrangement with Bristol Myers Squibb covering oncology data and models, valued at up to $137.5 million over five years. A separate arrangement involving Bristol Myers Squibb and Pathos, centered on data related to Alzheimer's disease and dementia, is valued at $55 million over five years.

Year-to-date data-licensing bookings exceeded $550 million, a figure According to market data, as bookings rather than revenue already recognized. Bookings convert to revenue over the life of a contract, so the figure indicates revenue that will be recognized later rather than current sales.

The company also announced a multi-year collaboration with Merck and Moderna aimed at supporting the possible commercial rollout of an individualized neoantigen therapy used alongside KEYTRUDA.

What is the Personalis acquisition and where does it stand?

Tempus has agreed to acquire Personalis, a cancer genomics company. The company said the transaction has now cleared regulatory review, and owners of Personalis stock are scheduled to vote on the proposal on November thirtieth.

A vote is the main remaining step that the release identifies, though closing conditions in Merger agreements often include others. The release itself is the primary source for the statement about regulatory clearance, and readers wanting the formal conditions should read the merger agreement and proxy materials filed by both companies.

For Tempus, the transaction would deepen its work on tests that track residual disease, the area where volume is growing fastest. It would also bring Personalis's laboratory capabilities in house, although the release did not quantify any cost savings or revenue effects from the combination.

How does artificial intelligence figure into the business?

The company's name places artificial intelligence at the center, and its pitch is that a very large set of linked clinical and molecular records lets it build models that help match patients with therapies and help drugmakers design trials. Much of the data segment is built on that proposition, and readers following AI Stocks will know it as one of the more concrete examples of AI revenue in healthcare.

The quarter also brought two clearances from the Food and Drug Administration, through the device clearance pathway, for artificial intelligence cardiology tools called ECG-PH and ECG-MR. Those are software products that analyze electrocardiograms. The release does not give revenue expectations for them, and regulatory clearance alone does not guarantee that clinicians will adopt a tool.

A further initiative is a research platform linking 100,000 whole genomes to longitudinal clinical records. Platforms of this scale are costly to build and are meant to support drug discovery partners, though the release does not describe the funding or the timeline.

What does the Balance Sheet and cash picture look like?

With about $854 million of cash and marketable securities at quarter-end, the company has a sizable cushion relative to its recent losses.

Adjusted EBITDA excludes stock-based compensation, which was very large in the quarter at about $51 million including related taxes. This is the main reason the adjusted measure is positive while the reported net result is still a loss. Readers comparing the two should note that stock-based pay is a real cost to existing stock owners even though it involves no cash outlay.

The balance sheet figure is also worth placing in context. A cash cushion of this size gives the company time to complete the Personalis transaction and to keep funding its data platform without immediately needing outside capital, although the release does not state any plans for the cash and further detail would be found in the quarterly report filed with the regulator.

Where does the company stand among its peers?

Tempus competes with large laboratories and specialist genomics firms in testing, and with data and analytics providers in the pharmaceutical services market. Its distinguishing claim is the combination of both, together with a large library of data.

The quarter shows the model working on several fronts at once: faster growth in the higher-margin data segment, higher volumes in oncology, and positive adjusted EBITDA. It also shows the weaker spots, including slow hereditary-test growth and a net loss that remains.

The company is a member of the broader group of artificial intelligence names that includes Nasdaq 100 constituents and much smaller firms alike, but its revenue comes from medical testing and licensing rather than from supplying computing infrastructure, a difference that shapes how it responds to economic and reimbursement conditions.

What else did the company announce in the weeks before the report?

The company's own news list shows a busy stretch. In late October it announced a European certification under the in vitro diagnostic regulation for its RNA sequencing test for solid tumor profiling, a step that matters for sales of the test in European markets. A few days earlier it expanded its strategic collaboration with Bristol Myers Squibb, which is the arrangement the quarterly release later described in dollar terms.

In mid-October it presented data showing that artificial intelligence pre-screening can help identify patients who should receive biomarker testing for a common type of lung cancer. In early October it announced the multi-year collaboration with Moderna and Merck. And in September it extended an existing data license with Recursion through late 2029 and added a new license for Recursion's RNA foundation model.

Taken together, these items show the same pattern as the financial results: a testing business that is adding regulatory credentials and clinical evidence, and a data business that is signing longer contracts with large drug developers. None of them is large enough on its own to define the quarter, but they provide context for the guidance raise.

How should the loss and the adjusted figures be read together?

There are three different measures in play. The reported net loss of about $15 million includes large non-cash items in both directions. The adjusted EBITDA figure of about $26 million excludes stock-based pay, depreciation and some other costs. The adjusted earnings per share figure of $0.07 sits between the two in how many items it removes.

Each measure answers a different question. Net loss shows what the company reported under accounting rules. Adjusted EBITDA shows the earnings power of operations before certain non-cash costs. Adjusted earnings per share gives a per-share view that is easier to compare with estimates compiled by data providers.

Anyone comparing the quarter with a year earlier should therefore use the same measure on both sides. On every measure the company supplied, the direction of change was favorable, but the size of the improvement differs, from a swing of about $65 million in the net loss to a gain of about $24 million in adjusted EBITDA.

What should readers watch from here for Tempus AI?

Readers new to the name may find it useful to separate the two stories. One is a clinical laboratory business with rising test volumes and the usual dependence on insurers. The other is a data and software business that licenses access to a large collection of de-identified records and models to drug developers. They share customers and infrastructure, but they are exposed to different forces, and the quarter showed progress in both.

The first item is the Personalis vote at the end of this month, followed by the closing process. The second is the fourth-quarter report, which will show whether revenue lands inside the raised guidance range and whether adjusted EBITDA reaches the maintained full-year figure.

A third is the pace at which data-licensing bookings convert into recognized revenue, and whether new agreements follow the Bristol Myers Squibb arrangements. A fourth is reimbursement news affecting minimal residual disease tests and other newer products, since coverage can shift volume sharply.

Beyond those, regulatory developments around artificial intelligence in medicine continue to evolve, and the clearance of two further tools shows the company is using the established device pathway.